Cargando…

Daclatasvir: potential role in hepatitis C [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964031/ http://dx.doi.org/10.2147/DDDT.S63655

Ejemplares similares

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]
Publicado: (2019)

Corrigendum: A novel substitution in NS5A enhances resistance of hepatitis C virus genotype 3 to daclatasvir
por: Fernandes Campos, Guilherme Rodrigues, et al.
Publicado: (2021)

Daclatasvir: potential role in hepatitis C
por: Lee, Choongho
Publicado: (2013)

Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]
Publicado: (2017)

Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
por: Gamal, Nesrine, et al.
Publicado: (2016)

Corrigendum in “Virus C genotype predisposes to primary hypothyroidism during interferon-α treatment for chronic hepatitis C”
por: Pavan, Maria Helena Postal, et al.
Publicado: (2013)

Hepatitis C Virus Reactivation Following COVID-19 Vaccination – A Case Report [Corrigendum]
Publicado: (2021)

Corrigendum to “Spontaneous Resolution of Symptomatic Hepatic Sarcoidosis”
por: Nguyen, Viva, et al.
Publicado: (2018)

Corrigendum to: Hepatitis C Seroprevalence Among Consecutive Labor and Delivery Admissions in Two New York City Hospitals
por: Kushner, Tatyana, et al.
Publicado: (2021)

Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C
por: Manolakopoulos, Spilios, et al.
Publicado: (2016)

Corrigendum to “Sphingosine-1-Phosphate Signaling in Immune Cells and Inflammation: Roles and Therapeutic Potential”
por: Aoki, Masayo, et al.
Publicado: (2016)

Corrigendum to “Transmission Model of Hepatitis B Virus with the Migration Effect”
por: Khan, Muhammad Altaf, et al.
Publicado: (2016)

Corrigendum to “The Controversial C5a Receptor C5aR2: Its Role in Health and Disease”
por: Zhang, Ting, et al.
Publicado: (2017)

Corrigendum: Magnetic Resonance Elastography and Diffusion Weighted Imaging in the Evaluation of Hepatic Fibrosis in Chronic Hepatitis B
por: Hennedige, Tiffany P., et al.
Publicado: (2020)

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]
Publicado: (2023)

Corrigendum to “Potential Extensions of the US FRAX Algorithm”
por: Osteoporosis, Journal of
Publicado: (2018)

Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019 – CORRIGENDUM
por: Lee Wilkinson, Anna, et al.
Publicado: (2022)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Corrigendum to “The Role of Medications in Causing Dry Eye”
por: Fraunfelder, Frederick T., et al.
Publicado: (2019)

Corrigendum: Estimation of C. elegans cell- and tissue volumes
Publicado: (2022)

Corrigendum to “An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients”
por: Enomoto, Hirayuki, et al.
Publicado: (2016)

Corrigendum: Direct-acting antiviral agents in Hepatitis C Virus infected renal allograft recipients: Treatment and outcome experience from single center
Publicado: (2018)

Antiviral Activity of Chitosan Nanoparticles Encapsulating Curcumin Against Hepatitis C Virus Genotype 4a in Human Hepatoma Cell Lines [Corrigendum]
Publicado: (2021)

Corrigendum to: Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors
Publicado: (2019)

Management of Hepatitis B Surface Antigen and Hepatitis C Antibody-Positive Patients by Departments Not Specializing in Hepatology at a Suburban University Hospital in Japan: A Single-Center Observational Study [Corrigendum]
Publicado: (2021)

Corrigendum to “Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy”
por: Than, Nwe Ni, et al.
Publicado: (2016)

Corrigendum to “Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp”
por: Mahamid, Mahmud, et al.
Publicado: (2017)

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
Publicado: (2015)

Optimizing care transitions: the role of the community pharmacist [Corrigendum]
Publicado: (2019)

Corrigendum to: Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies
por: Taramasso, Maurizio, et al.
Publicado: (2020)

Corrigendum to “The Role of Antioxidants in Skin Cancer Prevention and Treatment”
por: Godić, Aleksandar, et al.
Publicado: (2020)

The Role of Progestogens in Threatened and Idiopathic Recurrent Miscarriage [Corrigendum]
Publicado: (2020)

Corrigendum to: “Muscle-Organ Crosstalk: The Emerging Roles of Myokines”
Publicado: (2020)

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Corrigendum to “Antimetastatic Potentials of Dioscorea nipponica on Melanoma In Vitro and In Vivo”
por: Ho, Mao-Lin, et al.
Publicado: (2015)

Corrigendum to: The potential of component-resolved diagnosis in laboratory diagnostics of allergy
por: Dodig, Slavica, et al.
Publicado: (2018)

Corrigendum to “Cholesterol-Lowering Probiotics as Potential Biotherapeutics for Metabolic Diseases”
por: Kumar, Manoj, et al.
Publicado: (2022)

Corrigendum to “Protective Effects of Pretreatment with Oleanolic Acid in Rats in the Acute Phase of Hepatic Ischemia-Reperfusion Injury: Role of the PI3K/Akt Pathway”
por: Gui, Bo, et al.
Publicado: (2020)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Corrigendum: Efficacy of Real world Entecavir Therapy in Treatment NaïveChronic Hepatitis B Patients
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n3c9bc7q91o3deb8gk4i22leb9